First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors from the enLIGHTEN™ Discovery ...
The MarketWatch News Department was not involved in the creation of this content. Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce ...
A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a ...
How do tertiary lymphoid structures influence immunotherapy outcomes in Merkel cell carcinoma? Spatial proteomics reveals key ...
A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback